Lightnews — Scholar-powered news

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 19h

New open-access on FirstView: "Dignity and Abortion in Law, Philosophy, and Bioethics" by Eric Scarffe. "There is plenty for moral philosophy to learn from the case law surrounding abortion..." #dignity #abortion #LGBTQRights
www.cambridge.org/core/journal...

Dignity and Abortion in Law, Philosophy, and Bioethics
Eric Scarffe
Florida International University, United States
Abstract
Dignity has been a notoriously elusive concept to philosophers. Nevertheless, in the realms of politics, law, and policymaking, appeals to dignity
are frequent, and do not always align with the understandings most commonly endorsed by the philosophical literature. This paper considers
how“dignity” is frequently appealed to in ethical arguments about the permissibility of abortion, and argues that the judicial decisions related to
reproductive and LGBTQ+ rights over the past 30 years in the United States offer deep insights into the nature of“dignity” that philosophers
and other theorists ought to pay attention to. These insights not only have profound implications for our understanding of the nature of
“dignity,” but also for ethical analysis more broadly.
Keywords: Dignity; Abortion; Philosophy; Law; LGBTQ+ Rights

1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 1d

New Global Health Law column: "Renewing Nordic Leadership in Global Health" by Steven L.B. Jensen. "These efforts to renew global health policy ... have become even more timely in 2025 amid the US government defunding of global health and de facto closure of USAID." www.cambridge.org/core/journal...

Columns: Global Health Law
Renewing Nordic Leadership in Global Health
Steven L. B. Jensen
The Danish Institute for Human Rights, Copenhagen, Denmark
Abstract
Two expert groups on global health from Norway and Denmark have recently made important strides in reenergizing the debate on the role of
the Nordic countries in global health. Their tailored recommendations— emphasizing core values of human rights, equity, accountability, and
local ownership alongside health security— have proven influential at a time when new forms of international collaboration in global health are
urgently needed.
Keywords: Global Health; Denmark; Norway; Health Inequality; Sexual and Reproductive Health and Rights (SRHR); Nordic Leadership

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 9d

New open-access Teaching Health Law column: "Bridging the Theories and Practices of Healthcare and Law: A Student-Led Interprofessional Mock Trial Integrating Pharmacy Practice and Legal Education" by Larry J. Pittman, Kim G. Adcock, and Sally Earl. #PharmacyLaw
www.cambridge.org/core/journal...

Columns: Teaching Health Law
Bridging the Theories and Practices of Healthcare and Law: A Student-
Led Interprofessional Mock Trial Integrating Pharmacy Practice and
Legal Education
Larry J Pittman1 , Kim G Adcock2 and Sally Earl2
1Law, The University of Mississippi School of Law, United States and 2School of Pharmacy, University of Mississippi, United States
Abstract
This article describes a student-led interprofessional mock trial designed to explore the legal and regulatory dimensions of pharmacy practice
through collaboration between law students and pharmacy students at the University of Mississippi. Developed by the Interprofessional
Education (IPE) Board, the mock trial provides an immersive learning experience that simulates real-world legal proceedings involving
pharmacists. Students work in interdisciplinary teams to create original case files including fact patterns, deposition transcripts, and trial
evidence— based on scenarios involving professional misconduct, medication errors, or regulatory violations. Faculty advisors from both the
law and pharmacy school provide guidance to ensure accuracy and educational value. The mock trial involves multiple rounds judged by legal
and healthcare professionals, offering students a dynamic platform to develop professional communication, critical thinking, and collaborative
skills. Law students gain practical insight into healthcare law while pharmacy students deepen their understanding of legal accountability,
compliance, and the stages of a professional liability lawsuit. This interdisciplinary mock trial approach can especially be beneficial to law
schools and law students desiring practical skills in healthcare and malpractice litigation, given that— unlike medical schools’ and pharmacy
schools’ clinical programs— law schools’ courses involving medical liability issues frequently do not have a clinical component offering
practical experience in malpractice litigation. In sum, this article offers a descriptive a…

1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 13d

New on FirstView: "New VSED Advance Directive: Improved Documentation to Avoid Late-Stage Dementia" by Thaddeus Mason Pope, Lisa E. Brodoff, Erin Mae Glass, Paul T. Menzel, and Robb M. Miller. #EndOfLife #DementiaDirective
www.cambridge.org/core/journal...

New VSED Advance Directive: Improved Documentation to Avoid
Late-Stage Dementia
Thaddeus Mason Pope1 , Lisa E. Brodoff2, Erin Mae Glass3, Paul T. Menzel4, and Robb M. Miller5
1Mitchell Hamline School of Law, United States; 2Seattle University, United States; 3Chuckanut Law, United States; 4Pacific Lutheran University, United States and
5Independent, United States
Abstract
People use advance directives to express preferences that direct their future care when they lack decision-making capacity. One form of advance
directive, a“dementia directive,” records preferences about living in various stages of dementia. This is important because many Americans
want to avoid living with advanced progressive dementia. Unfortunately, traditional advance directives cannot dependably achieve this goal. In
contrast, some dementia directives can achieve this goal, by directing cessation of manually assisted feeding and drinking.
While many dementia directives have been published, most have gaps and omissions that thwart the goal of avoiding extended intolerable life
in advanced dementia. To overcome these problems, we formulated a new dementia directive. This article explains the value of this new
directive. We proceed in six stages. First, we review the prevalence of advanced dementia. Second, we identify the disadvantages of another
option for accomplishing the goal of not living into advanced dementia, preemptive VSED. Third, we distinguish notable court cases where
dementia directives were unsuccessful. Fourth, we review nine prominent dementia directives, noting how the Northwest Justice Project’
s
Advance Directive for VSED remedies those shortcomings. Fifth, we review this directive’s legal status. Sixth, we articulate its ethical
justification.
Keywords: VSED; Dementia; Advance Directive; Dementia Directive; End of Life; Minimal Comfort Feeding; MCF

1 2

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 16d

New on FirstView: "Human-Centric AI Governance: An Adaptive Public International Law Framework for Ethical and Inclusive AI Regulation in Public Health" by Farman Saeed Sedeeq and Percem Arman. #AI #ArtificialIntelligence
www.cambridge.org/core/journal...

Human-Centric AI Governance: An Adaptive Public International Law
Framework for Ethical and Inclusive AI Regulation in Public Health
Farman Saeed Sedeeq Faculty of Law, Near East University, Cyprus
and Percem Arman
Abstract
Artificial Intelligence (AI) is transforming public health, presenting both opportunities and ethical and legal challenges. This study adopts an
interdisciplinary approach, integrating legal doctrinal analysis, public health ethics, AI governance scholarship and a scoping review of
international legal instruments to evaluate and operationalize three core pillars: ethical accountability, regulatory adaptability and transpar-
ency. Through a scoping review of treaties, regional regulations and policy frameworks, the study maps jurisdictional gaps and proposes an
adaptive public law framework that addresses critical shortcomings in existing AI governance models, such as the WHO’s limited enforceability
and the GDPR’s rigid data-sharing rules. The framework introduces scalable, region-specific regulations to enhance interoperability while
respecting local governance needs. Its human-centric design, modular regulation and accountability mechanisms ensure adaptability across
diverse legal, cultural and health system contexts. Informed by case studies and a thematic synthesis of global best practices, this framework
offers policymakers and practitioners a structured yet flexible approach to balancing AI-driven innovation with ethical imperatives, promoting
equitable public health outcomes.
Keywords: Adaptive governance; Public health; Ethical accountability; Regulatory adaptability; Transparency

4

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 22d

New on FirstView: "Overlapping Method of Use Patents to Prevent Generic Entry" by Jin Park, @akesselheim.bsky.social , & S. Sean Tu describes "the role that use codes can play in blocking generic entry through a special regulatory pathway called skinny labeling..."
www.cambridge.org/core/journal...

Reposted by The Journal of Law, Medicine and Ethics

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 23d

The September issue of the Journal of Law, Medicine & Ethics is now online.

This issue features the open-access symposium Public Health, Markets, and Law, guest edited by @minacompetition.bsky.social and Imelda Maher, with incisive, in-depth articles.

Read now: www.cambridge.org/core/journal...

3 3

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 23d

The September issue of the Journal of Law, Medicine & Ethics is now online.

This issue features the open-access symposium Public Health, Markets, and Law, guest edited by @minacompetition.bsky.social and Imelda Maher, with incisive, in-depth articles.

Read now: www.cambridge.org/core/journal...

3 3

Reposted by The Journal of Law, Medicine and Ethics

Mary Guy @maryjguy.bsky.social · 23d

Delighted to see this Symposium of @jlme-journal.bsky.social on Public Health, Markets, and Law is now out.

Many thanks to @minacompetition.bsky.social and Imelda Maher!

My article considers #hospitals #stateaid and #SGEI

www.cambridge.org/core/journal...

3 4

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 28d

New open-access article on FirstView: "Constructing Opioid Legitimacy: The Canadian Pain Task Force’s Framing of the Overdose Crisis" by Daniel Eisenkraft Klein, Quinn Grundy, Ben Hawkins, and Robert Schwartz. #opioids #pain #PainManagement
www.cambridge.org/core/journal...

Constructing Opioid Legitimacy: The Canadian Pain Task Force’s
Framing of the Overdose Crisis
Daniel Eisenkraft Klein1,2,3 , Quinn Grundy4 , Ben Hawkins5 and Robert Schwartz1
1Dalla Lana School of Public Health, University of Toronto, Canada; 2Program On Regulation, Therapeutics, And Law, Brigham and Women’s Hospital, Boston, United
States; 3Harvard Medical School, United States; 4Lawrence Bloomberg Faculty of Nursing, University of Toronto, Canada and 5MRC Epidemiology Unit, University of
Cambridge, United Kingdom
Abstract
The opioid overdose crisis has become a global public health emergency, claiming more than 100,000 lives each year. In North America, shifting
opioid prescribing practices in response to the crisis have profoundly affected people living with chronic pain, who now face reduced access to
prescription opioids. Against this backdrop, pain stakeholders have become increasingly active in policymaking arenas to shape how opioids
and pain are understood. This study examines the Canadian Pain Task Force (CPTF)— a federal advisory body charged with creating a
national pain strategy— by analyzing its reports, public and patient consultations, and internal documents. Through qualitative framing
analysis, we find that stakeholders overwhelmingly depicted the overdose crisis as the result of illicit and irresponsible opioid use, while
positioning stigma as both a driver and consequence of the crisis that compounded the challenges faced by people with chronic pain. From these
problem definitions flowed policy proposals centered on expanding opioid access, reducing stigma, and advancing patient-centered care. These
findings demonstrate how pain stakeholders shape, and are simultaneously shaped by, opioid policy debates— with consequences for both
overdose prevention and chronic pain management.
Keywords: opioids; pain; overdose crisis; Canada; policy

1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · 29d

New open-access on FirstView: "ERISA and the Failure of Employers to Perform Their Fiduciary Duties: Evidence from a Survey of Health Plan Administrators" by @barakrichman.bsky.social , Amy Monahan, Jeffrey Pfeffer, and Sara Singer.
www.cambridge.org/core/journal...

ERISA and the Failure of Employers to Perform Their Fiduciary Duties:
Evidence from a Survey of Health Plan Administrators
Barak Richman1,2 , Amy Monahan3, Jeffrey Pfeffer4 and Sara Singer2
1School of Law, The George Washington University, United States; 2Stanford School of Medicine, Clinical Excellence Research Center, United States; 3University of
Minnesota Law School, United States and 4Stanford Graduate School of Business, United States
Abstract
Employers purchase health benefits for more than 60% of the nonelderly population, making employers both important custodians of
employee well-being and important actors in the health care ecosystem. Because employers typically have unilateral control over health and
retirement benefits, the federal Employee Retirement Income Security Act (ERISA), enacted in 1974, imposes fiduciary obligations on
employers when they manage or administer benefits. We provide evidence, from a novel survey of respondents who administer or oversee
health benefits for their companies, that many employers appear to neglect even the most basic of their fiduciary obligations to their employees.
This neglect may help explain the poor performance of employer plans in controlling costs and providing access to health care, and it suggests
that many employers may be vulnerable to liability from ERISA lawsuits.
Keywords: erisa; employer-sponsored insurance; employer fiduciaries; employer health plans; group health plans

3 2

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Sep 8

New on FirstView: "An Analysis of Anti-Bullying Laws in the United States" by Dane Alexander White, Gabrielle F. Miller, Kyle Rosenblum, Christopher Dunphy, Riley Wagner, and Molly Merrill-Francis. #bullying #LegalEpidemiology #MentalHealth
www.cambridge.org/core/journal...

An Analysis of Anti-Bullying Laws in the United States
, Gabrielle F. Miller1, Kyle Rosenblum1, Christopher Dunphy1, Riley Wagner2 and
Dane Alexander White1 Molly Merrill-Francis2
1Division of Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA and 2Division of
Violence Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Chamblee, GA, USA
Abstract
Bullying is a public health concern that results in diminished well-being for children and adolescents. One approach that lawmakers have taken
to address bullying is enacting anti-bullying laws, which require school districts to establish bullying prevention policies. In this study,
researchers used standard legal epidemiology methods to systematically retrieve and analyze anti-bullying laws in the United States (US). While
they found that every US state and the District of Columbia has a school anti-bullying law, there is wide variation in their scope and
requirements. Some jurisdictions specified requirements that school districts must implement in their anti-bullying policies, while others
deferred policy enactment entirely to school districts. Given the differences in requirements and scoping afforded in anti-bullying laws,
understanding the important components included in such policies can help provide policymakers and practitioners with information about
bullying prevention strategies across jurisdictions.
Keywords: Bullying; Legal Epidemiology; Adolescent Health; Mental Health; State Law

1 1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Sep 3

New open-access on FirstView: "EU’s Extraterritorial Obligations for Global Medicine Access Under the Convention on the Rights of Persons with Disability (CPRD)" by
‪@katperehudoff.bsky.social‬ from special issue "Public Health, Markets, and Law." #DisabilityRights
www.cambridge.org/core/journal...

Symposium Articles
EU’s Extraterritorial Obligations for Global Medicine Access Under the
Convention on the Rights of Persons with Disability (CPRD)
Katrina Perehudoff1,2,3,4,5
1University of Amsterdam Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands;
3Amsterdam Centre for European Studies, University of Amsterdam; 4Amsterdam Centre for European Law and Governance, University of Amsterdam and 5Medicines
Law & Policy, Amsterdam, the Netherlands
Abstract
Equitable access to medicines is vital for people with disabilities to receive effective, affordable, and quality treatment, helping preserve
functionality, prevent further disability, and promote social and economic inclusion. This paper explores the specific medicine needs of people
with disabilities in low- and middle-income countries (LMICs), focusing on the European Union’s (EU) extraterritorial legal obligations under
the Convention on the Rights of Persons with Disabilities (CRPD). As the first regional international organization to accede to a UN human
rights treaty, the EU offers a unique case for examining how international legal commitments extend beyond its borders. The paper outlines a
legal framework based on the CRPD to assess the EU’s responsibilities for ensuring access to medicines globally. This framework is applied to
two case studies: the EU’s internal joint COVID-19 vaccine procurement strategy and its external BioNTainer initiative for vaccine production
in Africa under Team Europe. The analysis finds that the EU falls short of its CRPD obligations, particularly in areas of technology transfer and
intellectual property sharing, which are essential for equitable global vaccine access. The paper concludes that the EU’s current actions do not
fulfill its human rights commitments to people with disabilities in LMICs.
Keywords: access to medicines; disability rights; pharmaceuticals; European Union; intellectual property

1 3

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Sep 2

New open-access article on FirstView: "Intellectual Property Rights and Global Access to Health Technologies During Pandemics: Reflecting on Vaccine Nationalism, COVID-19 & the WHO Pandemic Agreement Negotiations" by @aislingmcmahon.bsky.social. #PandemicAgreement
www.cambridge.org/core/journal...

Symposium Articles
Intellectual Property Rights and Global Access to Health Technologies
During Pandemics: Reflecting on Vaccine Nationalism, COVID-19 & the
WHO Pandemic Agreement Negotiations— The Need for Collective
Action and Institutional Change
Aisling M. McMahon
School of Law and Criminology, Maynooth University, Ireland
Abstract
Focusing on intellectual property rights (IPRs) and their role in global access to vaccines during the COVID-19 pandemic, this article argues
that key aspects of the current institutional system align towards delivering individualistic state/regional/rightsholders priorities in the use of
IPRs over pandemic health technologies. This played a key role in the vaccine nationalism and global vaccine inequity that emerged during the
pandemic. It critically analyzes the IPR provisions within the World Health Organisation’s Pandemic Agreement and negotiation process. It
argues that nationalistic/individualistic approaches toward the use of IPRs over health technologies also permeate such contexts. The final text
of the Agreement leaves considerable discretion to states around IPRs, and much will depend on how it is implemented in practice. For effective
future pandemic preparedness around how IPRs are used over health technologies, this article argues that a deeper bottom-up institutional
change is needed— one which offers nuanced strategies to balance the potential incentivization role of IPRs with the implications certain uses
of IPRs can have on access to downstream health technologies. A key element of this change is embedding a greater recognition of the range of
resources provided by entities (e.g. funders, biobanks, and universities) necessary in the successful development of health technologies,
including in pandemic contexts. Such entities should leverage these resources, including by attaching contractual conditions to access these,
which mandate avenues for downstream access to pandemic health technologies. In the longer term such…

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 29

New open-access on FirstView: "Maintaining the Integrity of the Biomedical Research Record Through Timely, Appropriate Corrective Action" by Lauren Walsh, Minal Caron, Carolyn T. Lye , Mark Barnes, and Barbara E. Bierer.
#ResearchIntegrity #PublicationEthics
www.cambridge.org/core/journal...

Columns: Currents in Contemporary Bioethics
Maintaining the Integrity of the Biomedical Research Record Through
Timely, Appropriate Corrective Action
Lauren Walsh1 , Minal Caron2 , Carolyn T. Lye2 , Mark Barnes2,3,4† and Barbara E. Bierer MD 4,5†
1Mass General Brigham and Harvard Medical School Center for Bioethics, Boston, Massachusetts; 2Ropes & Gray LLP, Boston, Massachusetts; 3Yale Law School, New Haven,
Connecticut; 4Multi-Regional Clinical Trials Center of the Brigham and Women’s Hospital and Harvard, Boston, Massachusetts and 5Department of Medicine, Harvard
Medical School and Brigham and Women’s Hospital, Boston, Massachusetts.
Abstract
the integrity of science.
Researchers, academic institutions, and journals have an ethical obligation to correct the research record expeditiously and publicly to maintain
Keywords: research integrity; publication ethics; research record; corrective action; corrections; retractions; expressions of concern

Reposted by The Journal of Law, Medicine and Ethics

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 26

New open access on FirstView: "Advance Market Commitments and Their Role in Public Innovation" by Sarosh Nagar, Anil Cacodcar, and @akesselheim.bsky.social analyzes what AMCs have done so far to fund innovation in medicine, and where they fall short. #ScienceFunding
www.cambridge.org/core/journal...

Columns: Health Policy Portal
Advance Market Commitments and Their Role in Public Innovation
Sarosh Nagar1,2 , Anil Cacodcar4 and Aaron S. Kesselheim1,3
1Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and
Women’s Hospital, Boston, MA; 2University College London, London, UK; 3Harvard Medical School, Boston, MA and 4Harvard College, Cambridge, MA
Abstract
Advance market commitments (AMCs) are gaining increasing attention as an alternative science funding mechanism to promote innovation in
medicine. In this paper, we first review the theory underlying AMCs, before analyzing two case studies of prior AMCs: the Gavi, the Vaccine
Alliance pneumococcal conjugate vaccine AMC launched in 2007 and the use of AMC-like mechanisms in Operation Warp Speed in the US.
We identify the empirical successes and limitations of AMCs in promoting research and development into new therapeutics and vaccine
candidates, highlighting both the strong promise of AMCs and the need to complement them with other science funding mechanisms to
promote innovation. We conclude with a series of recommendations to inform science policymakers.
Keywords: Science funding; Innovation policy; Metascience; Advance market commitment; Biomedical research

1 1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 26

New open access on FirstView: "Advance Market Commitments and Their Role in Public Innovation" by Sarosh Nagar, Anil Cacodcar, and @akesselheim.bsky.social analyzes what AMCs have done so far to fund innovation in medicine, and where they fall short. #ScienceFunding
www.cambridge.org/core/journal...

1 1

Reposted by The Journal of Law, Medicine and Ethics

Markus Frischhut @mrfrischhut.bsky.social · Aug 18

#Outnow: Parwani, P., @katperehudoff.bsky.social & @deruijter.bsky.social (2025). #Trust Beyond Borders: European #External #Regulatory Influence on #AccessToMedicines. The Journal of Law, #Medicine & #Ethics, 1–14. doi.org/10.1017/jme....

Trust Beyond Borders: European External Regulatory Influence on Access to Medicines | Journal of Law, Medicine & Ethics | Cambridge Core

Trust Beyond Borders: European External Regulatory Influence on Access to Medicines

doi.org

2 5

Reposted by The Journal of Law, Medicine and Ethics

Solomon Center @ YLS @solomonctryls.bsky.social · Aug 21

📚 In a new commentary for @jlme-journal.bsky.social‬, @solomonctryls.bsky.social faculty affiliate Lori Bruce urges stakeholders to promote safe access to psychedelics to avoid harmful patient outcomes and across-the-board restrictions on their use. www.cambridge.org/core/journal...

Responding to the Current Psychedelics Landscape: A Call for Cross-Sector Collaboration | Journal of Law, Medicine & Ethics | Cambridge Core

Responding to the Current Psychedelics Landscape: A Call for Cross-Sector Collaboration - Volume 53 Issue 2

www.cambridge.org

1 1

Reposted by The Journal of Law, Medicine and Ethics

Sam Varvastian @samvarvastian.bsky.social · Aug 18

The latest issue of the @jlme-journal.bsky.social is hot off the press, including my piece “Climate Change and Mental Health: A Human Rights Perspective”. Many thanks to the editorial team for their excellent work on this issue - it's an honor to be included. 1/3
www.cambridge.org/core/journal...

1 2 2

Reposted by The Journal of Law, Medicine and Ethics

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 15

We are proud to announce the publication of the Summer 2025 issue of The Journal of Law, Medicine & Ethics, with a diverse range of thought-provoking articles. If you are a print subscriber, you will receive your issue in the next couple of weeks.

Read it now at: www.cambridge.org/core/journal...

Cover of issue 53.2 of The Journal of Law, Medicine & Ethics.

3 2

Reposted by The Journal of Law, Medicine and Ethics

Benjamin Mason Meier @benjaminmasonmeier.bsky.social · Aug 15

New in @jlme-journal.bsky.social:

Legal Preparedness as a Foundation of Global Health Security
doi.org/10.1017/jme....

Advancing Legal Preparedness under the Global Health Security Agenda, we examine the GHSA imperative for capacity building & legal mapping to prepare for future emergencies.

1 1

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 15

We are proud to announce the publication of the Summer 2025 issue of The Journal of Law, Medicine & Ethics, with a diverse range of thought-provoking articles. If you are a print subscriber, you will receive your issue in the next couple of weeks.

Read it now at: www.cambridge.org/core/journal...

3 2

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 14

Are you a mid-career health or healthcare professional ready to impact federal policy? Engage in immersive policy training and serve as senior advisors to federally elected/appointed officials during this yearlong experience in Washington.
🔗Learn more and apply today: healthpolicyfellows.org/apply

Apply - RWJF Health Policy Fellows

FAQs Applications are now open through November 3, 2025 at 3pm ET. Applications for this solicitation must be submitted via MyRWJF, the RWJF online system. If you have not already done so, you will be...

healthpolicyfellows.org

Reposted by The Journal of Law, Medicine and Ethics

Anniek de Ruijter @deruijter.bsky.social · Aug 14

With @PramitiParwani & @katperehudoff.bsky.social, we explored EU pharma regulators’ role in access to medicines in low-income countries. Trust remains one-way, reinforcing dependencies; building regional regulatory capacity is key for global health 💫

The Journal of Law, Medicine and Ethics @jlme-journal.bsky.social · Aug 13

New open access on FirstView: "Trust Beyond Borders: European External Regulatory Influence on Access to Medicines" by Pramiti Parwani, ‪@katperehudoff.bsky.social‬, and @deruijter.bsky.social from the upcoming fall special issue "Public Health, Markets, and Law."
www.cambridge.org/core/journal...

Symposium Articles
Trust Beyond Borders: European External Regulatory Influence on
Access to Medicines
Pramiti Parwani1,2,3 , Katrina Perehudoff1,2,3 and Anniek de Ruijter1,2
1University of Amsterdam, Amsterdam Law School, Law for Health and Life, Netherlands; 2Amsterdam Institute for Global Health and Development, Netherlands and
3Amsterdam Centre for European Law and Governance, University of Amsterdam, Netherlands
Abstract
European institutions are widely recognized as wielding regulatory power in a globalized market, exporting its standards across borders and
between sectors. This paper asks what institutional dynamics catalyze European external regulatory impact on pharmaceutical governance in
low- and middle-income countries (LMICs). The research focuses on two European regulatory bodies, the European Medicines Agency (EMA)
and the European Patent Office (EPO), and explores the dynamics of their technocratic outreach beyond European borders. We find that trust
is a key underlying institutional dynamic facilitating some forms of European external relations. The agencies extend their influence through
technical assistance, collaboration, and work-sharing with LMIC regulators, fostering a one-sided relationship of“technocratic trust.” This
trust, reinforced by international regulatory frameworks that position the EMA and EPO as“trustworthy” regulators, enables these agencies to
expand their regulatory influence beyond Europe. By critically examining the impact of this trust-building on LMICs’ regulatory autonomy,
this research contributes to the broader discourse on European regulatory power in global health governance and highlights potential
implications for pharmaceutical markets and access in LMICs.
Keywords: European Regulatory Bodies; Pharmaceuticals Access; European Medicines Agency (EMA); European Patent Office (EPO); Trust

3 4